Galectin Therapeutics Inc.
News
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis...\n more…
Stock Traders Purchase Large Volume of Put Options on Galectin Therapeutics (NASDAQ:GALT)
Ticker Report Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) saw some unusual options trading activity on Thursday. Traders purchased 2,501 put options on the company. This represents an increase of...\n more…
Buy Rating Affirmed for Galectin Therapeutics Ahead of Phase 2b Interim Analysis and with Strong Cash Position
TipRanks Financial Blog Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Galectin Therapeutics (GALT - Research Report) and increased the price target to $1...\n more…
HC Wainwright Reaffirms "Buy" Rating for Galectin Therapeutics (NASDAQ:GALT)
Ticker Report Galectin Therapeutics (NASDAQ:GALT - Get Free Report)s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Friday...\n more…
GALT Stock Earnings: Galectin Therapeutics Misses EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nGALT stock results show that Galectin Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…